ClinicalTrials.gg
CompletedNCT01551758Updated May 31, 2017Results posted

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of FF/VI and Existing Maintenance Therapy in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 178 sites in United Kingdom. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-05-31.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,802
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.

Enrollment
4th of 25
2,802 · median 229
Started
2012
with 1 other
Phase 3
7 of 25
none open now
Registered
5th of 25
by date
Lead sponsor
21 of 25
GlaxoSmithKline

Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one is the 4th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 3, and was the 5th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444)) delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with the existing COPD maintenance therapy over twelve months in subjects diagnosed with COPD. This is a Phase III multi-centre, randomised open label study. Subjects who meet the eligibility criteria are randomised and will enter a 12 month treatment period.

Read the detailed description

This is a Phase III multi-centre, randomised open label study performed in subjects followed in primary care who have a diagnosis of and receive regular treatment for COPD in a localised geographical region of the UK

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • Exacerbation
  • Adult
  • COPD
  • Respiratory
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible for enrolment in the study must meet all of the following criteria:

  1. Type of subject: Subjects with documented GP diagnosis of , and currently receiving maintenance therapy
  2. : Subjects must be able to provide informed consent, have their consent signed and dated. Subjects must be able to complete the electronic subject questionnaires or allow a proxy to do so on their behalf.
  3. Gender and Age: Male or female subjects aged ≥40 years of age at Visit 1 A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms. However in questionable cases, a blood sample with FSH > 40MIU/ml and estradiol \<40pg/ml (\<140 pmol/L) is confirmatory. Or child bearing potential has a negative urine pregnancy test at Visit 2, and agrees to one of the highly effective and acceptable methods used consistently and correctly (i.e. in accordance with the approved product label and the instructions of the physician for the duration of the study - Visit 2 to the end of the study).
  4. Subjects with Exacerbation History
  5. Current COPD Maintenance Therapy

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

  1. Subjects with any life threatening condition (e.g. low probability (in the opinion of the GP/Investigator) of 12 month survival due to severity of or co-morbid condition) at the point of entry into the study.
  2. Other diseases/abnormalities: Subjects with historical or current evidence of uncontrolled or disease. Significant is defined as any disease that, in the opinion of the GP/ Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  3. Subjects with unstable COPD, defined as the occurrence of the following in the 2 weeks prior to Visit 2:

    • Acute worsening of COPD that is managed by the subject with or antibiotics or that requires treatment prescribed by a physician.
  4. Chronic user of oral corticosteroids: Subjects who, in the opinion of the GP/Investigator, are considered to be a chronic user of oral corticosteroids for respiratory or other indications (if unsure discuss with the medical monitor prior to screening)
  5. Drug/food allergy: Subjects with a history of to any of the study medications (e.g., beta-agonists, corticosteroid) or components of the inhalation powder (e.g., lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the GP/ Investigator, contraindicates the subject's participation will also be excluded.
  6. Medications: A subject must not have used any investigational drug treatment within 30 days prior to Visit 2 or within five half-lives (t½) of the prior investigational study (whichever is the longer of the two).
  7. Subjects who plan to move away from the geographical area where the study is being conducted during the study period and/or if subjects have not consented to their medical records being part of the electronic medical records database that is operational in the Salford area.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,802 participants (actual)

Study arms

  • Experimental
    FF/VI

    once daily via a Novel Dry Powder Inhaler

    Drug: FF/VI

  • Other
    Existing Maintenance Therapy

    Existing Maintenance Therapy: * Long acting bronchodilator therapy alone * ICS alone or in combination with a long acting bronchodilator * Triple maintenance therapy

    Other: Existing Maintenance Therapy

Interventions

  • DrugFF/VI

    Drug pages: Fluticasone furoate · Vilanterol

    FF/VI

  • OtherExisting Maintenance Therapy

    Existing Maintenance Therapy: * Long acting bronchodilator therapy alone * ICS alone or in combination with a long acting bronchodilator * Triple maintenance therapy

06

What researchers measure

Primary outcomes

  1. Mean Annual Rate of Moderate or Severe COPD Exacerbations

    Mean annual rate of moderate or severe COPD exacerbations during treatment were assessed. Moderate exacerbation: participant received exacerbation-related prescription of oral corticosteroids and/ or antibiotic (with/without National Health Service \[NHS\] contact) not requiring hospitalisation. Severe exacerbation: an exacerbation-related hospitalisation. Analysis method was Generalised Linear Model (GLM) assuming the negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable, adjusted for randomized treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in previous year and smoking status at baseline. Intent to treat (ITT) population: all randomised participants who received a prescription of study medication. Primary Efficacy Analysis Population: all ITT participants who had at least one moderate/severe exacerbation in the year prior to randomization

    Time frame: Up to 54 weeks

Secondary outcomes

  1. Number of Participants With Serious Adverse Events (SAEs) of Pneumonia During the Study

    Incidence of SAE of pneumonia was defined for each randomized treatment group as the proportion (number) of participants in that group who experienced at least one SAE of pneumonia in the Pneumonia Adverse Event of Special Interest subgroup during the treatment period (from start date of exposure to stop date of exposure + 28 days). Non-inferiority is demonstrated if the upper limit of the two-sided 95% confidence interval for the incidence ratio is less than 2. Serious Adverse Events of pneumonia are defined by the Pneumonia Special Interest Group, which for SAEs of pneumonia collected for these subjects includes the following preferred terms: Pneumonia, Pneumonia aspiration, Aspergillus infection, Empyema, Pneumonia streptococcal, Pneumonitis, Pulmonary tuberculosis.

    Time frame: Up to 58 weeks

  2. Mean Number of Serious Adverse Events of Pneumonia During the Study

    The mean number of SAE of pneumonia over the treatment period (from first date of exposure to last date of exposure + 28 days was calculated. Analysis was performed using a negative binomial regression model with covariates of randomised treatment and with logarithm of time on treatment as an offset variable.

    Time frame: Up to 58 weeks

  3. Time to the First Serious Adverse Event of Pneumonia Occuring in a Year

    The analysis method was a Cox proportional hazards model adjusted for randomized treatment. Analyses included those on-treatment SAEs of pneumonia that had an onset over the first 364 days of exposure, as defined. Participants who did not have an SAE of pneumonia during the first 364 days of the treatment period (start date of exposure to end date of exposure + 28 days were considered censored. Number of participants with event is presented.

    Time frame: Up to 52 weeks

  4. Number of COPD-related Secondary Care Contacts Expressed as Least Square Mean

    A COPD-related secondary care contact was defined as an inpatient admission or a specialist outpatient visit or an accident \& emergency (A\&E) contact. A participant with an A\&E contact and subsequent inpatient admission was considered to have had two healthcare contacts. Inpatient admissions recorded at two hospitals on the same day, this was counted as a single (inpatient admission) secondary care contact. COPD-related contacts were identified using predefined lists of ICD-10 codes, specialty descriptions and diagnosis codes recorded in the patients electronic health record (EHR). GLM assuming the negative binomial distribution with log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.

    Time frame: Up to 54 weeks

  5. Number of COPD-related Primary Care Contacts Expressed Using Least Square Mean

    A COPD-related primary care contact was defined as a primary care contact on a given calendar date with either a nurse, general physician (GP) or other healthcare professional that were considered as COPD-related, if the most prominent signs and symptoms the participant was presenting were as a direct result of the participant's COPD, as per Readcodes recorded in the patients electronic health record (EHR). The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.

    Time frame: Up to 54 weeks

  6. Number of All Secondary Care Contacts Expressed Using Least Square Mean

    A secondary care contact was defined as an inpatient admission or a specialist outpatient visit or an A\&E contact. A participant with an A\&E contact and subsequent inpatient admission was considered to have had two healthcare contacts. In the situation where inpatient admissions were recorded at two hospitals on the same day, this was counted as a single secondary care contact. The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomization stratification, number of moderate/severe COPD exacerbations in the previous year to randomization and smoking status at baseline.

    Time frame: Up to 54 weeks

  7. Number of All Primary Care Contacts Expressed Using Least Square Mean

    A primary care contact was defined as contact with a either a nurse, general practitioner, or other healthcare professional. The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.

    Time frame: Up to 54 weeks

  8. Time to an Event of Discontinuation of Initial Therapy Occurring in a Year

    Initial therapy was defined as the treatment that the subject was randomised to at randomisation. Discontinuation of initial therapy was defined as any modification of initial therapy. These included stepping up, stepping down or switching to another class/class combination, or withdrawal from the study. Switching within the same drug class did not count unless participant switched from FF/VI to a different ICS/LABA. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of discontinuation of initial therapy was measured from the date of randomisation (i.e., exposure start date) to the date of discontinuation of initial therapy to which the participant was randomized, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without discontinuing the initial therapy (censored). Number of participants with event is presented.

    Time frame: Up to 364 days

  9. Time to the Addition of a Further COPD Controller Medication Occurring in a Year

    The date of an event for addition of a further COPD controller medication was defined as the exposure start date of the first modified treatment medication that included a new COPD maintenance therapy of a new class of drug (to the initial therapy) during the study treatment period, as collected on the investigational product page of the eCRF. Participants who did not add any COPD controller medication during the study were censored at the end of the treatment period (Day 364). This was equivalent to stepping up, defined as the addition of at least one new class of drug. The probability of an event was measured from the date of randomisation (i.e., treatment initiation) to the date of a change event. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. Number of participants with event is presented.

    Time frame: Up to 364 days

  10. Time to First Moderate/Severe Exacerbations Occurring in a Year

    The date of an event for moderate / severe COPD exacerbation was defined as the exacerbation onset date. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of a first moderate / severe exacerbation was measured from the date of randomisation (i.e., treatment initiation) to the onset date of first moderate or severe COPD exacerbation, as recorded on eCRF, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without any moderate or severe exacerbations (censored). Participants who completed the study without a moderate or severe COPD exacerbation and analyses of time to first moderate/severe exacerbation were censored at Day 364. Number of participants with event is presented.

    Time frame: Up to 364 days

  11. Time to First Moderate/Severe Exacerbations on Initial Therapy Occurring in a Year

    The date of an event for moderate / severe COPD exacerbation was defined as the exacerbation onset date. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of first moderate / severe exacerbation on initial therapy was measured from the date of randomisation (i.e., exposure start date) to the onset date of first moderate or severe COPD exacerbation, or to the date of discontinuation of initial therapy (analysis was censored at date of discontinuation of initial therapy) for participants who completed the study without any moderate or severe exacerbations on initial therapy. Number of participants with event is presented.

    Time frame: Up to 364 days

  12. Time to First Severe Exacerbations Occurring in a Year

    The date of an event for severe exacerbation was defined as the exacerbation onset date. Participants who completed the study without a severe exacerbation were censored. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of first severe exacerbation was measured from the date of randomisation (i.e., treatment initiation) to the onset date of first severe exacerbation, as recorded on eCRF, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without any severe exacerbations (censored). At Day 364, all participants who have not experienced a severe exacerbation are considered censored, regardless of whether their on-treatment phase continues beyond day 364, including those who withdrew early. Number of participants with event is presented.

    Time frame: Up to 364 days

  13. Number of Participants With Fatal Serious Adverse Events of Pneumonia

    All SAEs included in the AE subgroup of special interest of "pneumonia" were considered as an SAE of pneumonias. A fatal SAE was defined as a SAE with outcome of fatal for study participant. The number of participants with fatal SAEs of pneumonia was assessed over 14 months.

    Time frame: Upto 58 weeks

  14. Number of Participants With Non-serious Adverse Drug Reactions (ADR)

    The number of participants with non-serious ADRs was assessed for up to 54 weeks. An ADR is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, for which there is a reasonable possibility that the untoward occurrence is causally related to the medicinal product. A non-serious ADR included one of the following: exacerbation of chronic or intermittent pre-existing condition; signs, symptoms, or the clinical sequelae of a suspected interaction; signs, symptoms, or new conditions detected or diagnosed after study treatment administration.

    Time frame: Up to 54 weeks

  15. Number of Participants With Serious Adverse Events

    SAEs assessed included medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a significant medical event in the investigator's judgment, or is an event of possible drug-induced liver injury with hyperbilirubinaemia. SAEs were includes if the onset date was on or after the treatment start date and on or before the treatment stop date. However, the window for an SAE of pneumonia was longer and included 28 days post study treatment stop date.

    Time frame: Up to 56 weeks

  16. Number of Participants With Serious Adverse Drug Reactions

    A serious adverse drug reactions (SADR) is any untoward medical occurrence suspected to be medicinal product-related that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

    Time frame: Upto 12 months

07

Results

Posted Mar 7, 2017

Participant flow

This was a multicentre, randomized, stratified, open-label study to evaluate the effectiveness and safety of fluticasone fuorate (FF)/vilanterol (VI) in participants followed in primary care who had a diagnosis of and received regular treatment for Chronic Obstructive Pulmonary Disease (COPD).

Participant flow — Overall Study
MilestoneUsual CareFluticasone Furoate (FF)/Vilanterol (VI) 100 mcg/25 mcg
Started14031396
Completed13091291
Not completed94105
Withdrew: Adverse event2943
Withdrew: Lack of efficacy01
Withdrew: Protocol violation56
Withdrew: Met protocol-defined stopping criteria810
Withdrew: Lost to follow-up2925
Withdrew: Physician decision93
Withdrew: Withdrawal by subject1417

Outcome measures

PrimaryMean Annual Rate of Moderate or Severe COPD Exacerbations

Mean annual rate of moderate or severe COPD exacerbations during treatment were assessed. Moderate exacerbation: participant received exacerbation-related prescription of oral corticosteroids and/ or antibiotic (with/without National Health Service \[NHS\] contact) not requiring hospitalisation. Severe exacerbation: an exacerbation-related hospitalisation. Analysis method was Generalised Linear Model (GLM) assuming the negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable, adjusted for randomized treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in previous year and smoking status at baseline. Intent to treat (ITT) population: all randomised participants who received a prescription of study medication. Primary Efficacy Analysis Population: all ITT participants who had at least one moderate/severe exacerbation in the year prior to randomization

Time frame:
Up to 54 weeks
Reported as:
Least squares mean · Exacerbations per participant per year
Mean Annual Rate of Moderate or Severe COPD Exacerbations
Exacerbations per participant per yearUsual CareFF/VI 100 mcg/25 mcg
Mean Annual Rate of Moderate or Severe COPD Exacerbations1.90 (1.80 to 2.01)1.74 (1.65 to 1.84)
Statistical analysis
  • Usual Care vs FF/VI 100 mcg/25 mcg · Generalized Linear Model · p = =0.025 · Adjusted treatment ratio: 0.92 · 95% CI 0.85 to 0.99
SecondaryNumber of Participants With Serious Adverse Events (SAEs) of Pneumonia During the Study

Incidence of SAE of pneumonia was defined for each randomized treatment group as the proportion (number) of participants in that group who experienced at least one SAE of pneumonia in the Pneumonia Adverse Event of Special Interest subgroup during the treatment period (from start date of exposure to stop date of exposure + 28 days). Non-inferiority is demonstrated if the upper limit of the two-sided 95% confidence interval for the incidence ratio is less than 2. Serious Adverse Events of pneumonia are defined by the Pneumonia Special Interest Group, which for SAEs of pneumonia collected for these subjects includes the following preferred terms: Pneumonia, Pneumonia aspiration, Aspergillus infection, Empyema, Pneumonia streptococcal, Pneumonitis, Pulmonary tuberculosis.

Time frame:
Up to 58 weeks
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events (SAEs) of Pneumonia During the Study
ParticipantsUsual CareFF/VI 100 mcg/25 mcg
Number of Participants With Serious Adverse Events (SAEs) of Pneumonia During the Study8394
Statistical analysis
  • Usual Care vs FF/VI 100 mcg/25 mcg · Incidence ratio: 1.1 · 95% CI 0.9 to 1.5Calculated as % of participants who had at least one SAE of pneumonia in the FF/VI group divided by the % of participants who had at least one SAE of pneumonia in the Usual Care group
SecondaryMean Number of Serious Adverse Events of Pneumonia During the Study

The mean number of SAE of pneumonia over the treatment period (from first date of exposure to last date of exposure + 28 days was calculated. Analysis was performed using a negative binomial regression model with covariates of randomised treatment and with logarithm of time on treatment as an offset variable.

Time frame:
Up to 58 weeks
Reported as:
Least squares mean · Mean Number of SAE
Mean Number of Serious Adverse Events of Pneumonia During the Study
Mean Number of SAEUsual CareFF/VI 100 mcg/25 mcg
Mean Number of Serious Adverse Events of Pneumonia During the Study0.07 (0.06 to 0.09)0.08 (0.06 to 0.09)
Statistical analysis
  • Usual Care · Generalized linear model · p = 0.632 · Adjusted treatment ratio: 1.08 · 95% CI 0.79 to 1.47
SecondaryTime to the First Serious Adverse Event of Pneumonia Occuring in a Year

The analysis method was a Cox proportional hazards model adjusted for randomized treatment. Analyses included those on-treatment SAEs of pneumonia that had an onset over the first 364 days of exposure, as defined. Participants who did not have an SAE of pneumonia during the first 364 days of the treatment period (start date of exposure to end date of exposure + 28 days were considered censored. Number of participants with event is presented.

Time frame:
Up to 52 weeks
Reported as:
Number · Participants
Time to the First Serious Adverse Event of Pneumonia Occuring in a Year
ParticipantsUsual CareFF/VI 100 mcg/25 mcg
Time to the First Serious Adverse Event of Pneumonia Occuring in a Year8089
Statistical analysis
  • Usual Care vs FF/VI 100 mcg/25 mcg · Cox proportional hazards model · p = =0.439 · Hazard ratio (hr): 1.13 · 95% CI 0.83 to 1.52
SecondaryNumber of COPD-related Secondary Care Contacts Expressed as Least Square Mean

A COPD-related secondary care contact was defined as an inpatient admission or a specialist outpatient visit or an accident \& emergency (A\&E) contact. A participant with an A\&E contact and subsequent inpatient admission was considered to have had two healthcare contacts. Inpatient admissions recorded at two hospitals on the same day, this was counted as a single (inpatient admission) secondary care contact. COPD-related contacts were identified using predefined lists of ICD-10 codes, specialty descriptions and diagnosis codes recorded in the patients electronic health record (EHR). GLM assuming the negative binomial distribution with log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.

Time frame:
Up to 54 weeks
Reported as:
Least squares mean · Contacts per participant per year
Number of COPD-related Secondary Care Contacts Expressed as Least Square Mean
Contacts per participant per yearUsual CareFF/VI 100 mcg/25 mcg
Number of COPD-related Secondary Care Contacts Expressed as Least Square Mean1.48 (1.30 to 1.67)1.57 (1.39 to 1.78)
Statistical analysis
  • Usual Care vs FF/VI 100 mcg/25 mcg · Generalized linear model · p = 0.488 · Adjusted treatment ratio: 1.06 · 95% CI 0.89 to 1.27
SecondaryNumber of COPD-related Primary Care Contacts Expressed Using Least Square Mean

A COPD-related primary care contact was defined as a primary care contact on a given calendar date with either a nurse, general physician (GP) or other healthcare professional that were considered as COPD-related, if the most prominent signs and symptoms the participant was presenting were as a direct result of the participant's COPD, as per Readcodes recorded in the patients electronic health record (EHR). The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.

Time frame:
Up to 54 weeks
Reported as:
Least squares mean · Contacts per participant per year
Number of COPD-related Primary Care Contacts Expressed Using Least Square Mean
Contacts per participant per yearUsual CareFF/VI 100 mcg/25 mcg
Number of COPD-related Primary Care Contacts Expressed Using Least Square Mean2.46 (2.34 to 2.58)2.42 (2.30 to 2.53)
Statistical analysis
  • Usual Care vs FF/VI 100 mcg/25 mcg · Generalized linear model · p = 0.622 · Adjusted treatment ratio: 0.98 · 95% CI 0.92 to 1.05
SecondaryNumber of All Secondary Care Contacts Expressed Using Least Square Mean

A secondary care contact was defined as an inpatient admission or a specialist outpatient visit or an A\&E contact. A participant with an A\&E contact and subsequent inpatient admission was considered to have had two healthcare contacts. In the situation where inpatient admissions were recorded at two hospitals on the same day, this was counted as a single secondary care contact. The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomization stratification, number of moderate/severe COPD exacerbations in the previous year to randomization and smoking status at baseline.

Time frame:
Up to 54 weeks
Reported as:
Least squares mean · Contacts per participant per year
Number of All Secondary Care Contacts Expressed Using Least Square Mean
Contacts per participant per yearUsual CareFF/VI 100 mcg/25 mcg
Number of All Secondary Care Contacts Expressed Using Least Square Mean9.36 (8.74 to 10.02)9.81 (9.17 to 10.51)
Statistical analysis
  • Usual Care vs FF/VI 100 mcg/25 mcg · Generalized Linear Model · p = 0.336 · Adjusted treatment ratio: 1.05 · 95% CI 0.95 to 1.15
SecondaryNumber of All Primary Care Contacts Expressed Using Least Square Mean

A primary care contact was defined as contact with a either a nurse, general practitioner, or other healthcare professional. The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.

Time frame:
Up to 54 weeks
Reported as:
Least squares mean · Contacts per participant per year
Number of All Primary Care Contacts Expressed Using Least Square Mean
Contacts per participant per yearUsual CareFF/VI 100 mcg/25 mcg
Number of All Primary Care Contacts Expressed Using Least Square Mean18.88 (18.06 to 19.74)21.20 (20.27 to 22.16)
Statistical analysis
  • Usual Care vs FF/VI 100 mcg/25 mcg · Generalized Linear Model · p = <0.001 · Adjusted treatment ratio: 1.12 · 95% CI 1.05 to 1.20
SecondaryTime to an Event of Discontinuation of Initial Therapy Occurring in a Year

Initial therapy was defined as the treatment that the subject was randomised to at randomisation. Discontinuation of initial therapy was defined as any modification of initial therapy. These included stepping up, stepping down or switching to another class/class combination, or withdrawal from the study. Switching within the same drug class did not count unless participant switched from FF/VI to a different ICS/LABA. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of discontinuation of initial therapy was measured from the date of randomisation (i.e., exposure start date) to the date of discontinuation of initial therapy to which the participant was randomized, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without discontinuing the initial therapy (censored). Number of participants with event is presented.

Time frame:
Up to 364 days
Reported as:
Number · Participants
Time to an Event of Discontinuation of Initial Therapy Occurring in a Year
ParticipantsUsual CareFF/VI 100 mcg/25 mcg
Time to an Event of Discontinuation of Initial Therapy Occurring in a Year219374
Statistical analysis
  • Usual Care vs FF/VI 100 mcg/25 mcg · Cox proportional hazards model · p = <0.001 · Hazard ratio (hr): 1.89 · 95% CI 1.60 to 2.23A hazard ratio \<1 indicates a lower risk with FF/VI compared with Usual Care.
SecondaryTime to the Addition of a Further COPD Controller Medication Occurring in a Year

The date of an event for addition of a further COPD controller medication was defined as the exposure start date of the first modified treatment medication that included a new COPD maintenance therapy of a new class of drug (to the initial therapy) during the study treatment period, as collected on the investigational product page of the eCRF. Participants who did not add any COPD controller medication during the study were censored at the end of the treatment period (Day 364). This was equivalent to stepping up, defined as the addition of at least one new class of drug. The probability of an event was measured from the date of randomisation (i.e., treatment initiation) to the date of a change event. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. Number of participants with event is presented.

Time frame:
Up to 364 days
Reported as:
Number · Participants
Time to the Addition of a Further COPD Controller Medication Occurring in a Year
ParticipantsUsual CareFF/VI 100 mcg/25 mcg
Time to the Addition of a Further COPD Controller Medication Occurring in a Year14272
Statistical analysis
  • Usual Care vs FF/VI 100 mcg/25 mcg · Cox proprotional hazards model · p = <0.001 · Hazard ratio (hr): 0.49 · 95% CI 0.37 to 0.66A hazard ratio \<1 indicates a lower risk with FF/VI compared with Usual Care
SecondaryTime to First Moderate/Severe Exacerbations Occurring in a Year

The date of an event for moderate / severe COPD exacerbation was defined as the exacerbation onset date. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of a first moderate / severe exacerbation was measured from the date of randomisation (i.e., treatment initiation) to the onset date of first moderate or severe COPD exacerbation, as recorded on eCRF, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without any moderate or severe exacerbations (censored). Participants who completed the study without a moderate or severe COPD exacerbation and analyses of time to first moderate/severe exacerbation were censored at Day 364. Number of participants with event is presented.

Time frame:
Up to 364 days
Reported as:
Number · Participants
Time to First Moderate/Severe Exacerbations Occurring in a Year
ParticipantsUsual CareFF/VI 100 mcg/25 mcg
Time to First Moderate/Severe Exacerbations Occurring in a Year977947
Statistical analysis
  • Usual Care vs FF/VI 100 mcg/25 mcg · Cox porportional hazards model · p = 0.111 · Hazard ratio (hr): 0.93 · 95% CI 0.85 to 1.02A hazard ratio \<1 indicates a lower risk with FF/VI compared with Usual Care
SecondaryTime to First Moderate/Severe Exacerbations on Initial Therapy Occurring in a Year

The date of an event for moderate / severe COPD exacerbation was defined as the exacerbation onset date. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of first moderate / severe exacerbation on initial therapy was measured from the date of randomisation (i.e., exposure start date) to the onset date of first moderate or severe COPD exacerbation, or to the date of discontinuation of initial therapy (analysis was censored at date of discontinuation of initial therapy) for participants who completed the study without any moderate or severe exacerbations on initial therapy. Number of participants with event is presented.

Time frame:
Up to 364 days
Reported as:
Number · Participants
Time to First Moderate/Severe Exacerbations on Initial Therapy Occurring in a Year
ParticipantsUsual CareFF/VI 100 mcg/25 mcg
Time to First Moderate/Severe Exacerbations on Initial Therapy Occurring in a Year943852
Statistical analysis
  • Usual Care vs FF/VI 100 mcg/25 mcg · Cox porportional hazards model · p = 0.081 · Hazard ratio (hr): 0.92 · 95% CI 0.84 to 1.01
SecondaryTime to First Severe Exacerbations Occurring in a Year

The date of an event for severe exacerbation was defined as the exacerbation onset date. Participants who completed the study without a severe exacerbation were censored. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of first severe exacerbation was measured from the date of randomisation (i.e., treatment initiation) to the onset date of first severe exacerbation, as recorded on eCRF, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without any severe exacerbations (censored). At Day 364, all participants who have not experienced a severe exacerbation are considered censored, regardless of whether their on-treatment phase continues beyond day 364, including those who withdrew early. Number of participants with event is presented.

Time frame:
Up to 364 days
Reported as:
Number · Participants
Time to First Severe Exacerbations Occurring in a Year
ParticipantsUsual CareFF/VI 100 mcg/25 mcg
Time to First Severe Exacerbations Occurring in a Year97122
Statistical analysis
  • Usual Care vs FF/VI 100 mcg/25 mcg · Cox proportional hazards model · p = 0.075 · Hazard ratio (hr): 1.27 · 95% CI 0.98 to 1.66
SecondaryNumber of Participants With Fatal Serious Adverse Events of Pneumonia

All SAEs included in the AE subgroup of special interest of "pneumonia" were considered as an SAE of pneumonias. A fatal SAE was defined as a SAE with outcome of fatal for study participant. The number of participants with fatal SAEs of pneumonia was assessed over 14 months.

Time frame:
Upto 58 weeks
Reported as:
Number · Participants
Number of Participants With Fatal Serious Adverse Events of Pneumonia
ParticipantsUsual CareFF/VI 100 mcg/25 mcg
Number of Participants With Fatal Serious Adverse Events of Pneumonia1313
SecondaryNumber of Participants With Non-serious Adverse Drug Reactions (ADR)

The number of participants with non-serious ADRs was assessed for up to 54 weeks. An ADR is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, for which there is a reasonable possibility that the untoward occurrence is causally related to the medicinal product. A non-serious ADR included one of the following: exacerbation of chronic or intermittent pre-existing condition; signs, symptoms, or the clinical sequelae of a suspected interaction; signs, symptoms, or new conditions detected or diagnosed after study treatment administration.

Time frame:
Up to 54 weeks
Reported as:
Number · Participants
Number of Participants With Non-serious Adverse Drug Reactions (ADR)
ParticipantsUsual CareFF/VI 100 mcg/25 mcg
Number of Participants With Non-serious Adverse Drug Reactions (ADR)88192
SecondaryNumber of Participants With Serious Adverse Events

SAEs assessed included medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a significant medical event in the investigator's judgment, or is an event of possible drug-induced liver injury with hyperbilirubinaemia. SAEs were includes if the onset date was on or after the treatment start date and on or before the treatment stop date. However, the window for an SAE of pneumonia was longer and included 28 days post study treatment stop date.

Time frame:
Up to 56 weeks
Reported as:
Number · Participants
Number of Participants With Serious Adverse Events
ParticipantsUsual CareFF/VI 100 mcg/25 mcg
Number of Participants With Serious Adverse Events383404
SecondaryNumber of Participants With Serious Adverse Drug Reactions

A serious adverse drug reactions (SADR) is any untoward medical occurrence suspected to be medicinal product-related that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

Time frame:
Upto 12 months
Reported as:
Number · Participants
Number of Participants With Serious Adverse Drug Reactions
ParticipantsUsual CareFF/VI 100 mcg/25 mcg
Number of Participants With Serious Adverse Drug Reactions1023

Adverse events

Collected over Serious adverse events (SAEs; from Visit 1) and non-serious adverse drug reactions (from Visit 2) were collected from study medication start until the end of treatment (up to Visit 6 or withdrawal, ie, approximately 54 weeks). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Usual Care—383/1,403 (27.3%)40/1,403 (2.9%)
FF/VI 100 mcg/25 mcg—404/1,396 (28.9%)56/1,396 (4%)
Most frequent serious events
Showing 10 of 458
Most frequent serious events
EventUsual CareFF/VI 100 mcg/25 mcg
PneumoniaInfections and infestations81/140389/1396
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders70/140386/1396
Infective exacerbation of chronic obstructive airway diseaseInfections and infestations47/140350/1396
Atrial fibrillationCardiac disorders29/140327/1396
Respiratory failureRespiratory, thoracic and mediastinal disorders24/140315/1396
Acute kidney injuryRenal and urinary disorders16/140323/1396
FallInjury, poisoning and procedural complications9/140315/1396
Liver function test abnormalInvestigations6/140315/1396
CellulitisInfections and infestations9/140314/1396
Acute myocardial infarctionCardiac disorders9/140313/1396
Most frequent other events
Most frequent other events
EventUsual CareFF/VI 100 mcg/25 mcg
Oral candidiasisInfections and infestations40/140356/1396

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Usual CareFF/VI 100 mcg/25 mcgTotal
Mean66.7 ± 9.9366.6 ± 9.9066.7 ± 9.92
Sex: Female, Male
Sex: Female, Male(Participants)Usual CareFF/VI 100 mcg/25 mcgTotal
Female6716981369
Male7326981430
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Usual CareFF/VI 100 mcg/25 mcgTotal
African American/African Heritage358
Asian-Central/South Asian Heritage5611
Asian-East Asian Heritage101
Asian-South East Asian Heritage101
White-Arabic/North African Heritage134
White-White/Caucasian/European Heritage138713762763
Mixed Race5510
08

Study locations

178 sites
  • GSK Investigational Site
    Altrincham, Cheshire WA14 2NW, United Kingdom
  • GSK Investigational Site
    Altrincham, Cheshire WA14 5ET, United Kingdom
  • GSK Investigational Site
    Altrincham, Cheshire WA14 5GR, United Kingdom
  • GSK Investigational Site
    Altrincham, Cheshire WA14 5NH, United Kingdom
  • GSK Investigational Site
    Altrincham, Cheshire WA14 5PF, United Kingdom
  • GSK Investigational Site
    Bowdon, Cheshire WA14 3BD, United Kingdom
  • GSK Investigational Site
    Cheadle Hulme, Cheshire SK8 5EG, United Kingdom
  • GSK Investigational Site
    Cheadle, Cheshire SK8 6LQ, United Kingdom
  • GSK Investigational Site
    Edgeley, Cheshire SK3 9LQ, United Kingdom
  • GSK Investigational Site
    Gatley, Cheshire SK84NG, United Kingdom
  • GSK Investigational Site
    Heald Green, Cheshire SK8 3QA, United Kingdom
  • GSK Investigational Site
    Sale, Cheshire M33 2RH, United Kingdom
  • GSK Investigational Site
    Sale, Cheshire M33 2UP, United Kingdom
  • GSK Investigational Site
    Sale, Cheshire M33 4BR, United Kingdom
  • GSK Investigational Site
    Sale, Cheshire M33 7SS, United Kingdom
  • GSK Investigational Site
    Stockport, Cheshire SK3 9NX, United Kingdom
  • GSK Investigational Site
    Timperley, Cheshire WA15 7DD, United Kingdom
  • GSK Investigational Site
    Timperley, Cheshire WA15 7UN, United Kingdom
  • GSK Investigational Site
    Altrincham, Greater Manchester WA14 2DW, United Kingdom
  • GSK Investigational Site
    Altrincham, Greater Manchester WA15 6PH, United Kingdom
  • GSK Investigational Site
    Broadway, Davyhulme, Greater Manchester M41 7WJ, United Kingdom
  • GSK Investigational Site
    Irlam, Manchester, Greater Manchester M44 5LH, United Kingdom
  • GSK Investigational Site
    Irlam, Greater Manchester M44 5LH, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M20 1EB, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M20 2DN, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M20 2RN, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M20 3BG, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M20 4SS, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M20 6WF, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M22 4DH, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M22 5DW, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M22 5RB, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M22 5RX, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M22 9UE, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M23 1JP, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M23 1JX, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M23 9AB, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M27 9LB, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M32 0DF, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M32 0PA, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M32 0RW, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M33 2TB, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M33 3HF, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M33 4WB, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M33 5JD, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M33 5PN, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M33 7SS, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M33 7XN, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M41 0NA, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M41 0SE, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M41 0TZ, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M41 5AA, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M41 7FN, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M41 7WJ, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M41 8AA, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester WA15 6BP, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester WA15 7UN, United Kingdom
  • GSK Investigational Site
    Newall Green, Greater Manchester M23 2SY, United Kingdom
  • GSK Investigational Site
    Northenden, Greater Manchester M22 4DH, United Kingdom
  • GSK Investigational Site
    Northern Moor, Greater Manchester M23 0BX, United Kingdom
  • GSK Investigational Site
    Pendlebury, Manchester, Greater Manchester M27 8HP, United Kingdom
  • GSK Investigational Site
    Pendlebury, Greater Manchester M27 8HP, United Kingdom
  • GSK Investigational Site
    Salford, Manchester, Greater Manchester M7 4TP, United Kingdom
  • GSK Investigational Site
    Salford, Greater Manchester M6 5PW, United Kingdom
  • GSK Investigational Site
    Salford, Greater Manchester M6 6ES, United Kingdom
  • GSK Investigational Site
    Salford, Greater Manchester M6 7HL, United Kingdom
  • GSK Investigational Site
    Salford, Greater Manchester M7 1RD, United Kingdom
  • GSK Investigational Site
    Stretford, Greater Manchester M32 9BD, United Kingdom
  • GSK Investigational Site
    Timperley, Greater Manchester WA15 6PH, United Kingdom
  • GSK Investigational Site
    Withington, Greater Manchester M20 1EY, United Kingdom
  • GSK Investigational Site
    Wythenshawe, Greater Manchester M22 0EP, United Kingdom
  • GSK Investigational Site
    Wythenshawe, Greater Manchester M22 5RN, United Kingdom
  • GSK Investigational Site
    Wythenshawe, Greater Manchester M22 5RX, United Kingdom
  • GSK Investigational Site
    Cadishead, Manchester, M44 5DD, United Kingdom
  • GSK Investigational Site
    Cheadle, SK8 5BB, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 0EA, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 0EJ, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 0LS, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 0NU, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 0PF, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 0TU, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 7JW, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 7NA, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 8AR, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 8JA, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 8QD, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 9PS, United Kingdom
  • GSK Investigational Site
    Eccles, M30 0TU, United Kingdom
  • GSK Investigational Site
    Ellenbrook, Manchester, M28 1PB, United Kingdom
  • GSK Investigational Site
    Irlam, Manchester, M44 5LH, United Kingdom
  • GSK Investigational Site
    Irlam, Manchester, M44 6AJ, United Kingdom
  • GSK Investigational Site
    Irlam, Manchester, M44 6BL, United Kingdom
  • GSK Investigational Site
    Irlam, Manchester, M44 6FE, United Kingdom
  • GSK Investigational Site
    Irlam, Manchester, M44 6FN, United Kingdom
  • GSK Investigational Site
    Irlam, Salford, M44 6DP, United Kingdom
  • GSK Investigational Site
    Irlam, Salford, M44 6ZS, United Kingdom
  • GSK Investigational Site
    Little Hulton, Manchester, M28 0AY, United Kingdom
  • GSK Investigational Site
    Little Hulton, Manchester, M28 0BA, United Kingdom
  • GSK Investigational Site
    Little Hulton, Manchester, M38 9GH, United Kingdom
  • GSK Investigational Site
    Little Hulton, Manchester, M38 9GR, United Kingdom

Showing the first 100 of 178 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Vestbo J, Waterer G, Leather D, Crim C, Diar Bakerly N, Frith L, Jacques L, Harvey C, Satia I, Woodcock A; Salford Lung Study Investigators. Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD. Eur Respir J. 2022 May 19;59(5):2102899. doi: 10.1183/13993003.02899-2021. Print 2022 May. PubMed 35273031 ↗
  • Bakerly ND, Browning D, Boucot I, Crawford J, McCorkindale S, Stein N, New JP. The impact of fluticasone furoate/vilanterol on healthcare resource utilisation in the Salford Lung Study in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211001013. doi: 10.1177/17534666211001013. PubMed 33781142 ↗
  • Sperrin M, Webb DJ, Patel P, Davis KJ, Collier S, Pate A, Leather DA, Pimenta JM. Chronic obstructive pulmonary disease exacerbation episodes derived from electronic health record data validated using clinical trial data. Pharmacoepidemiol Drug Saf. 2019 Oct;28(10):1369-1376. doi: 10.1002/pds.4883. Epub 2019 Aug 5. PubMed 31385428 ↗
  • Bakerly ND, Woodcock A, Collier S, Leather DA, New JP, Crawford J, Harvey C, Vestbo J, Boucot I. Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups. Respir Med. 2019 Feb;147:58-65. doi: 10.1016/j.rmed.2018.12.016. Epub 2019 Jan 10. PubMed 30704700 ↗
  • Woodcock A, Boucot I, Leather DA, Crawford J, Collier S, Bakerly ND, Hilton E, Vestbo J. Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability. Eur Respir J. 2018 Feb 21;51(2):1701531. doi: 10.1183/13993003.01531-2017. Print 2018 Feb. PubMed 29467200 ↗
  • Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, McCorkindale S, Collier S, Crawford J, Frith L, Harvey C, Svedsater H, Woodcock A; Salford Lung Study Investigators. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. N Engl J Med. 2016 Sep 29;375(13):1253-60. doi: 10.1056/NEJMoa1608033. Epub 2016 Sep 4. PubMed 27593504 ↗
  • Bakerly ND, Woodcock A, New JP, Gibson JM, Wu W, Leather D, Vestbo J. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease. Respir Res. 2015 Sep 4;16(1):101. doi: 10.1186/s12931-015-0267-6. PubMed 26337978 ↗
  • New JP, Bakerly ND, Leather D, Woodcock A. Obtaining real-world evidence: the Salford Lung Study. Thorax. 2014 Dec;69(12):1152-4. doi: 10.1136/thoraxjnl-2014-205259. Epub 2014 Mar 6. Erratum In: Thorax. 2015 Oct;70(10):1008. doi: 10.1136/thoraxjnl-2014-205259corr1. PubMed 24603195 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in Nov 2015, 44 months.

Results were first posted in Mar 2017, 1 year 3 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 44 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2012
First posted
Mar 13, 2012
StartActual
Mar 13, 2012
Primary completionActual
Nov 24, 2015
CompletionActual
Nov 24, 2015
Results first posted
Mar 7, 2017
Last update
May 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01551758
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 13, 2012
Start date
Mar 13, 2012
Primary completion
Nov 24, 2015
Completion
Nov 24, 2015
Results posted
Mar 7, 2017
Last update
May 31, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol

Start the discussion